Microarray Testing For Hematologic Disorders

Microarray testing is available using a custom designed chip (KANCERRAY) for research purposes.

Platform For Oncology aCGH

We use the Agilent 180K custom designed oligonucleotide array platform, which was specifically designed and validated by Pittsburgh Cytogenetics Laboratory for the sole purpose of identifying acquired genomic alterations, DNA copy number gains and losses, associated with hematological cancers, such as CLL, CML, AML, T-cell and B-cell ALL. The 180,000 oligonucleotides on the KANCERRAY cover 900 genes involved in carcinogenesis and 78 cancer syndromes with a maximum probe spacing of one probe for every 25 Kb throughout the genome and one probe for every 1 Kb in clinical regions. (PMID: 26299921; PMID: 28214896).

• Cancer Related Genes Covered By Kancerray
• Cancer Syndromes Covered By PCL Kancerray

Clinical Indication For Microarray Analysis

• Samples with normal Karyotype
• Samples with poor chromosomal morphology
• Samples with in vitro growth failure

Specimens For Oncology Array Test

• Bone marrow aspirate
• Oncology blood

Advantages For Oncology Microarray Analysis

• No in vitro cell culture is needed for microarray analysis.
• Microarray testing can provide copy number gain and loss when the conventional cytogenetics analysis is a failure due to poor growth.
• Microarray testing can detect copy number imbalances in the resolution of 150Kb.
• Microarray testing can rapidly detect and characterize numerical chromosomal abnormalities and LOH in one experiment.
• Microarray testing has high sensitivity and specificity.

Limitations For Oncology Microarray Analysis

• Array CGH will not detect balanced translocations, polyploidy or inversions.
• Array CGH will not detect low level mosaicism (<20%).